Search results for "allergen immunotherapy"

showing 10 items of 24 documents

The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective.

2020

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the…

AllergyAllergen immunotherapymedicine.medical_specialtybusiness.industryHealth technologymedicine.diseaseRhinitis AllergicAsthmaTelemedicinelaw.inventionClinical trialRandomized controlled triallawDesensitization ImmunologicmedicineImmunology and AllergyHumansIntensive care medicinebusinessmHealthPatient stratificationAsthmaThe journal of allergy and clinical immunology. In practice
researchProduct

Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review

2018

BACKGROUND Allergen immunotherapy (AIT) with mould extracts has been performed for many years but the final demonstration of its clinical efficacy is still missing, due to the small number of studies and their inconsistent results. OBJECTIVE To systematically review efficacy and safety of AIT for the treatment of respiratory allergies to moulds. DESIGN The primary outcomes were safety and reduction of symptoms (Symptom Score, SS) and medication use (Medication Score, MS) in patients treated with AIT compared to controls. The strength of the evidence was graded based on the risk of bias, consistency and magnitude of effect, according to the GRADE Working Group's guide. DATA SOURCES Medline, …

Allergen immunotherapymedicine.medical_specialtyAllergyAntigens FungalImmunologyMEDLINECochrane LibraryPlacebo03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicineHypersensitivityHumansImmunology and AllergyMedicineAnti-Asthmatic Agents030212 general & internal medicineAsthmaClinical Trials as Topicbusiness.industryFungiAllergensmedicine.diseasePhenotypeTreatment Outcome030228 respiratory systemDesensitization ImmunologicSample size determinationbusinessClinical & Experimental Allergy
researchProduct

The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis

2017

Background Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. Methods Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-…

Allergen immunotherapymedicine.medical_specialtybusiness.industryCochrane Librarymedicine.diseasemedicine.disease_causelaw.invention03 medical and health sciences0302 clinical medicineAllergenPharmacotherapy030228 respiratory systemOtorhinolaryngologyRandomized controlled triallawMeta-analysisInternal medicinemedicineImmunology and AllergyObservational study030212 general & internal medicinebusinessAsthmaInternational Forum of Allergy & Rhinology
researchProduct

Current therapeutical strategies for allergic rhinitis

2018

Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option.This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the…

Allergen immunotherapyRhinitis allergicTreatment outcomeHistamine Antagonistsmacromolecular substancesmedicine.disease_cause03 medical and health sciences0302 clinical medicineAllergenimmune system diseasesmedicineHumansPharmacology (medical)AsthmaPharmacologybusiness.industryHistamine antagonistsGeneral MedicineAtopic dermatitisrespiratory systemmedicine.diseaseRhinitis Allergicrespiratory tract diseasesbody regionsTreatment OutcomeDesensitization Immunologic030220 oncology & carcinogenesisImmunologybusiness030217 neurology & neurosurgeryExpert Opinion on Pharmacotherapy
researchProduct

Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

2021

International audience; The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to dete…

Allergen immunotherapyEndotypeMESH: AllergensMESH: HypersensitivityImmunologyDiseaseBioinformaticsMESH: Precision Medicine03 medical and health sciences0302 clinical medicinemolecular diagnosisHypersensitivityImmunology and AllergyMedicineHumansPrecision MedicineMESH: Desensitization Immunologic[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyMESH: Humansbusiness.industryMechanism (biology)MESH: GenomicsGenomicspersonalized medicineAllergenstreatable traitsMolecular diagnosticsOmics3. Good healthBiomarker (cell)omicsallergen immunotherapy; molecular diagnosis; omics; personalized medicine; treatable traits030228 respiratory systemDesensitization Immunologicallergen immunotherapyPersonalized medicinebusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology030215 immunology
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie – ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion) – Positionspapier …

2020

Allergen immunotherapyCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemOtorhinolaryngologyDermatology clinicPandemicImmunologyPosition paperMedicinebusinessCoronavirus InfectionsLaryngo-Rhino-Otologie
researchProduct

Harmful effect of immunotherapy in children with combined snail and mite allergy

2002

Abstract Background: With respect to allergy, the possibility of cross-reactivity between snail and mite is well recognized, and anecdotal reports suggesting that allergen immunotherapy with mite extract can worsen snail-induced allergy exist. Objective: We describe the effect of immunotherapy in 4 children with snail-mite allergy. Methods: Four children (1 boy and 3 girls; 9-13 years of age) had consistent clinical histories (mild immediate respiratory symptoms after ingestion) and positive skin reactions for allergy to snail. They also had mite-induced asthma and were therefore prescribed subcutaneous specific immunotherapy and subsequently followed. Results: Several months (8-25) after s…

MiteMaleAllergen immunotherapyAllergyAdolescentSnails; Animals; Food Hypersensitivity; Immunotherapy; Humans; Mites; Child; Adolescent; Male; Female; Cross ReactionsSnailsImmunologyCross Reactionsmedicine.disease_causeAllergenFood allergyparasitic diseasesmedicineAnimalsHumansImmunology and AllergyIngestionFood allergy; House dust mite; Immunotherapy; SnailChildAsthmaHouse dust miteMitesintegumentary systembiologyAnimalbusiness.industrymedicine.diseasebiology.organism_classificationSnailImmunologyFemaleImmunotherapybusinessFood HypersensitivityAnaphylaxisHuman
researchProduct

Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies

2015

The number of people over 65 is increasing around the world. At present, between 5 and 10% of allergic diseases affect the elderly. In particular, rhinitis is increasing worldwide; the presence of high comorbidity makes the therapy of asthma even more complicated. With reference to dermatological allergies, the dryness of the skin favors the onset of allergic contact and atopic dermatitis, while the senescence of mucous membranes and the impaired secretion of polymeric IgA could be linked to food allergy. Overcoming the problem of adverse drug reaction is limited by the diagnostic difficulty in patients taking multiple drugs. In addition, some drugs, such as β-blockers, angiotensin-converti…

MaleAgingAllergymedicine.medical_specialtyAIT-allergen immunotherapyHealth Services for the AgedImmunologyDrug allergydermatological allergieanaphylaxiDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioelderlyFood allergyHypersensitivitymedicineHumansImmunology and AllergyAsthmaimmunosenescencefood allergybusiness.industryMedicine (all)Atopic dermatitismedicine.diseaseDermatologyPatient ComplianceFemaleallergic rhinitibusinessallergic asthmadrug allergyAnaphylaxisAdverse drug reactionHumanExpert Review of Clinical Immunology
researchProduct

The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis.

2017

Background Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. Methods Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-…

allergic rhinitisPyroglyphidaenew allergen sensitizationasthmameta-analysiDesensitization ImmunologicAnti-Allergic Agentsallergen immunotherapyHypersensitivityAnimalsHumansImmunizationAntigens DermatophagoidesChildRandomized Controlled Trials as TopicInternational forum of allergyrhinology
researchProduct